CA2859934A1 - Hayley's comet ii - Google Patents
Hayley's comet ii Download PDFInfo
- Publication number
- CA2859934A1 CA2859934A1 CA2859934A CA2859934A CA2859934A1 CA 2859934 A1 CA2859934 A1 CA 2859934A1 CA 2859934 A CA2859934 A CA 2859934A CA 2859934 A CA2859934 A CA 2859934A CA 2859934 A1 CA2859934 A1 CA 2859934A1
- Authority
- CA
- Canada
- Prior art keywords
- cultivar
- cannabidiolic acid
- cannabis
- cannabinoid
- profile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H1/00—Processes for modifying genotypes ; Plants characterised by associated natural traits
- A01H1/04—Processes of selection involving genotypic or phenotypic markers; Methods of using phenotypic markers for selection
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Developmental Biology & Embryology (AREA)
- Environmental Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Abstract
A new cultivar of medical cannabis has been bred that renders relatively large amounts of cannabidiolic acid (mg/gram ground flower weight)...greater than 10%.
The cultivar moved from an outdoor to indoor environment produced similar levels of cannabidiolic acid (CBD-A) and similar cannabinoid profiles. Reproduced asexually, the same (greater than 10%) cannabidiolic acid amounts were rendered and this remains constant crop to crop. THC levels do not change between 20 and 30% of that of the CBD-A concentration. High Pressure Liquid Chromatography (HPLC) determines cannabinoid profiles where the amounts of the three most abundant cannabinoids (tetrahydrocannabinol, cannabinol, and cannabidiol) and their acids are quantified. The cannabinoid profile relates directly to the physiological effects of the plant as a medicine. In addition, a genetic fingerprint of the strain has been generated using gel electrophoresis. Strains high in cannabidiolic acid are rare since breeding has favored the high THC strains for their psychoactive effects (recreational cannabis). Hayley's Comet II provides a unique cannabinoid profile containing large concentrations of CBA-A making it useful for medicaments for seizure disorder, pain and inflammation.
The cultivar moved from an outdoor to indoor environment produced similar levels of cannabidiolic acid (CBD-A) and similar cannabinoid profiles. Reproduced asexually, the same (greater than 10%) cannabidiolic acid amounts were rendered and this remains constant crop to crop. THC levels do not change between 20 and 30% of that of the CBD-A concentration. High Pressure Liquid Chromatography (HPLC) determines cannabinoid profiles where the amounts of the three most abundant cannabinoids (tetrahydrocannabinol, cannabinol, and cannabidiol) and their acids are quantified. The cannabinoid profile relates directly to the physiological effects of the plant as a medicine. In addition, a genetic fingerprint of the strain has been generated using gel electrophoresis. Strains high in cannabidiolic acid are rare since breeding has favored the high THC strains for their psychoactive effects (recreational cannabis). Hayley's Comet II provides a unique cannabinoid profile containing large concentrations of CBA-A making it useful for medicaments for seizure disorder, pain and inflammation.
Description
Background of the Invention:
Patent No. 2694325 speaks to synthetic analogues of Cannabidiol; the invention described here refers to natural cannabidiolic acid compounds and their decarboxylated derivatives.
Patent No. 2499210 speaks to cannabidiol in a highly pure form, greater than 95%, that can be used in medical studies, whereas the invention described here is a means of obtaining cannabidiolic acid in its natural form, plus inclusion of the other natural cannabinoids.
Patent No. 2411831 speaks to uses of cannabidiol in pure form, the invention described here addresses cannabidiolic acid in its natural form and means of obtaining CBD-A.
Patent No. 2424356 speaks to extraction of tetrahydrocannabinol and cannabidiol using super critical fluid extraction whereas the invention described here employs not extraction of compounds from the plant.
Patent No. 2692539 speaks to ratios of cannabidiol to cannabivarin as antagonists to the CB1 and CB2 receptors, whereas the invention described here is merely a continues source of cannabidiolic acid and other carboxylated cannabinoids.
A strain of cannabis with high concentrations of cannabidiolic acid was bred, whereby with asexual reproduction cannabidiolic acid concentrations (as determined by HPLC) remains consistent and the genetic fingerprint remains inimitable within cannabis subspecies. The DNA profile was generated using gel electrophoresis and compared to a number of common strains of similar type.
The unique DNA fingerprint plus the cannabinoid profile characterize the strain, plus morphological description, cloning, growth and pest resistance add to distinguishing this plant form others of its type.
Objectives of the Invention:
1.) An objective of the invention is to preserve a strain of cannabis with unique cannabinoid and DNA profiles, represented by high cannabidiolic acid to tetrahydrocannabinolic acid ratios.
Patent No. 2694325 speaks to synthetic analogues of Cannabidiol; the invention described here refers to natural cannabidiolic acid compounds and their decarboxylated derivatives.
Patent No. 2499210 speaks to cannabidiol in a highly pure form, greater than 95%, that can be used in medical studies, whereas the invention described here is a means of obtaining cannabidiolic acid in its natural form, plus inclusion of the other natural cannabinoids.
Patent No. 2411831 speaks to uses of cannabidiol in pure form, the invention described here addresses cannabidiolic acid in its natural form and means of obtaining CBD-A.
Patent No. 2424356 speaks to extraction of tetrahydrocannabinol and cannabidiol using super critical fluid extraction whereas the invention described here employs not extraction of compounds from the plant.
Patent No. 2692539 speaks to ratios of cannabidiol to cannabivarin as antagonists to the CB1 and CB2 receptors, whereas the invention described here is merely a continues source of cannabidiolic acid and other carboxylated cannabinoids.
A strain of cannabis with high concentrations of cannabidiolic acid was bred, whereby with asexual reproduction cannabidiolic acid concentrations (as determined by HPLC) remains consistent and the genetic fingerprint remains inimitable within cannabis subspecies. The DNA profile was generated using gel electrophoresis and compared to a number of common strains of similar type.
The unique DNA fingerprint plus the cannabinoid profile characterize the strain, plus morphological description, cloning, growth and pest resistance add to distinguishing this plant form others of its type.
Objectives of the Invention:
1.) An objective of the invention is to preserve a strain of cannabis with unique cannabinoid and DNA profiles, represented by high cannabidiolic acid to tetrahydrocannabinolic acid ratios.
2.) A further objective of the inventions is to preserve a strain of cannabis with high ratios of CBD-A to THC-A to be used in medicaments.
3.) A further objective of the invention is to propagate the strain for yields of CBD-A
4.) A further objective of the invention is to propagate the strain for use in medicaments for chronic pain and seizure disorder.
5.) A further objective of the invention is to propagate a strain with consistent cannabinoid profiles of high CBD-A to THC-A ratios.
6.) A further objective of the invention is to use this strain to breed other strains with a similar high CBD-A to THC-A ratio.
Summary of the Invention A single cultivar of cannabis has been bred with distinct HPLC and DNA
profiles.
The cultivar is asexually reproduced with cloning such that a cannabinoid profile with greater than 100 mg/gram (of ground, dried, flower weight) CBD-A is consistently produced and the THC concentration consistently less than 150 mg/gram, of ground flower weight.
Summary of the Invention A single cultivar of cannabis has been bred with distinct HPLC and DNA
profiles.
The cultivar is asexually reproduced with cloning such that a cannabinoid profile with greater than 100 mg/gram (of ground, dried, flower weight) CBD-A is consistently produced and the THC concentration consistently less than 150 mg/gram, of ground flower weight.
Claims
Claims:
Claim 1: A method whereby a unique cannabinoid profile as determined by High Pressure Liquid Chromatography (HPLC), defines a specific cultivar of asexually reproducing cannabis.
Claim 2: A method whereby a genetic profile (fingerprint), defines a specific cultivar of asexually reproducing cannabis.
Claim 3: A method whereby a cannabidiolic acid concentration of greater than mg/gram (of ground flower weight), is consistently found in the specific cultivar.
Claim 4: A method whereby a tetrahydrocannabinol concentration of less than 15%
(of ground flower weight), is consistently found in the specific cultivar of asexually reproducing cannabis.
Claim 5: A method whereby the DNA profile at locus Cind 16FR (bp) differs from other comparable strains and having a distinct fragment pattern characteristic of the cultivar.
Claim 6: A method whereby the DNA profile at locus Cind1FR differs from other comparable strains and having a distinct fragment pattern characteristic of the cultivar.
Claim 7: A method whereby the DNA profile at locus Cind5 differs from other comparable strains and having a distinct fragment pattern characteristic of the cultivar.
Claim 8: A method whereby the DNA profile at locus Cind24FR differs from other comparable strains and having a distinct fragment pattern characteristic of the cultivar.
Claim 9: The cultivar (Hayley's Comet), described here provides a cannabinoid profile useful in the treatment of epilepsy, chronic pain and imflammation.
Claim 1: A method whereby a unique cannabinoid profile as determined by High Pressure Liquid Chromatography (HPLC), defines a specific cultivar of asexually reproducing cannabis.
Claim 2: A method whereby a genetic profile (fingerprint), defines a specific cultivar of asexually reproducing cannabis.
Claim 3: A method whereby a cannabidiolic acid concentration of greater than mg/gram (of ground flower weight), is consistently found in the specific cultivar.
Claim 4: A method whereby a tetrahydrocannabinol concentration of less than 15%
(of ground flower weight), is consistently found in the specific cultivar of asexually reproducing cannabis.
Claim 5: A method whereby the DNA profile at locus Cind 16FR (bp) differs from other comparable strains and having a distinct fragment pattern characteristic of the cultivar.
Claim 6: A method whereby the DNA profile at locus Cind1FR differs from other comparable strains and having a distinct fragment pattern characteristic of the cultivar.
Claim 7: A method whereby the DNA profile at locus Cind5 differs from other comparable strains and having a distinct fragment pattern characteristic of the cultivar.
Claim 8: A method whereby the DNA profile at locus Cind24FR differs from other comparable strains and having a distinct fragment pattern characteristic of the cultivar.
Claim 9: The cultivar (Hayley's Comet), described here provides a cannabinoid profile useful in the treatment of epilepsy, chronic pain and imflammation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2859934A CA2859934A1 (en) | 2014-09-22 | 2014-09-22 | Hayley's comet ii |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2859934A CA2859934A1 (en) | 2014-09-22 | 2014-09-22 | Hayley's comet ii |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2859934A1 true CA2859934A1 (en) | 2016-03-22 |
Family
ID=55539873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2859934A Abandoned CA2859934A1 (en) | 2014-09-22 | 2014-09-22 | Hayley's comet ii |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2859934A1 (en) |
Cited By (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2541191A (en) * | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| US10092525B2 (en) | 2014-10-14 | 2018-10-09 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
| CN108743571A (en) * | 2018-08-07 | 2018-11-06 | 云南汉木森生物科技有限责任公司 | Prevent, treat the pharmaceutical composition and preparation method thereof of epilepsy |
| CN110632224A (en) * | 2019-09-16 | 2019-12-31 | 福建省中科生物股份有限公司 | Establishment method of hemp plant fingerprint spectrum |
| US10583096B2 (en) | 2016-03-31 | 2020-03-10 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10603288B2 (en) | 2014-06-17 | 2020-03-31 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10709671B2 (en) | 2015-06-17 | 2020-07-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10729665B2 (en) | 2011-09-29 | 2020-08-04 | Gw Pharma Limited | Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| US10765643B2 (en) | 2014-10-14 | 2020-09-08 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
| US10918608B2 (en) | 2014-10-14 | 2021-02-16 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
| US11065227B2 (en) | 2016-08-25 | 2021-07-20 | GW Research Limited | Use of cannabinoids in the treatment of multiple myeloma |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
| US11160795B2 (en) | 2020-02-27 | 2021-11-02 | GW Research Limited | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| US11229612B2 (en) | 2016-07-01 | 2022-01-25 | GW Research Limited | Parenteral formulations |
| US11291631B2 (en) | 2016-07-01 | 2022-04-05 | GW Research Limited | Oral cannabinoid formulations |
| US11426362B2 (en) | 2017-02-17 | 2022-08-30 | GW Research Limited | Oral cannabinoid formulations |
| US11679087B2 (en) | 2016-12-16 | 2023-06-20 | GW Research Limited | Use of cannabinoids in the treatment of Angelman syndrome |
| US11806319B2 (en) | 2018-01-03 | 2023-11-07 | GW Research Limited | Pharmaceutical composition comprising a cannabinoid |
| US12161607B2 (en) | 2017-02-27 | 2024-12-10 | Jazz Pharmaceuticals Research Uk Limited | Combination of cannabinoids in the treatment of leukemia |
| US12263139B2 (en) | 2017-06-23 | 2025-04-01 | Jazz Pharmaceuticals Research Uk Limited | Use of cannabidiol in the treatment of tuberous sclerosis complex |
| US12357586B2 (en) | 2011-01-04 | 2025-07-15 | Jazz Pharmaceuticals Research Uk Limited | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| US12383567B2 (en) | 2017-12-01 | 2025-08-12 | Jazz Pharmaceuticals Research Uk Limited | Use of cannabinoids in the treatment of epilepsy |
| US12569505B2 (en) | 2022-08-12 | 2026-03-10 | Jazz Pharmaceuticals Research Uk Limited | Oral solid dosage forms comprising cannabinoids |
| US12661365B2 (en) | 2020-06-18 | 2026-06-23 | Jazz Pharmaceuticals Research Uk Limited | Use of cannabidiol in the treatment of epilepsy |
-
2014
- 2014-09-22 CA CA2859934A patent/CA2859934A1/en not_active Abandoned
Cited By (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12357586B2 (en) | 2011-01-04 | 2025-07-15 | Jazz Pharmaceuticals Research Uk Limited | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| US10729665B2 (en) | 2011-09-29 | 2020-08-04 | Gw Pharma Limited | Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| US11318109B2 (en) | 2011-09-29 | 2022-05-03 | Gw Pharma Limited | Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| US12121499B2 (en) | 2011-09-29 | 2024-10-22 | Gw Pharma Ltd. | Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| US11311498B2 (en) | 2014-06-17 | 2022-04-26 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11701330B2 (en) | 2014-06-17 | 2023-07-18 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11766411B2 (en) | 2014-06-17 | 2023-09-26 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11963937B2 (en) | 2014-06-17 | 2024-04-23 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10603288B2 (en) | 2014-06-17 | 2020-03-31 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11154516B2 (en) | 2014-06-17 | 2021-10-26 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10918608B2 (en) | 2014-10-14 | 2021-02-16 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
| US10709673B2 (en) | 2014-10-14 | 2020-07-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10765643B2 (en) | 2014-10-14 | 2020-09-08 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
| US12318356B2 (en) | 2014-10-14 | 2025-06-03 | Jazz Pharmaceuticals Research Uk Limited | Use of cannabinoids in the treatment of epilepsy |
| US10849860B2 (en) | 2014-10-14 | 2020-12-01 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11633369B2 (en) | 2014-10-14 | 2023-04-25 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11446258B2 (en) | 2014-10-14 | 2022-09-20 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10966939B2 (en) | 2014-10-14 | 2021-04-06 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10709674B2 (en) | 2014-10-14 | 2020-07-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11065209B2 (en) | 2014-10-14 | 2021-07-20 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
| US11096905B2 (en) | 2014-10-14 | 2021-08-24 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11400055B2 (en) | 2014-10-14 | 2022-08-02 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
| US11154517B2 (en) | 2014-10-14 | 2021-10-26 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10092525B2 (en) | 2014-10-14 | 2018-10-09 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
| US10111840B2 (en) | 2014-10-14 | 2018-10-30 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
| US12427160B2 (en) | 2014-10-14 | 2025-09-30 | Jazz Pharmaceuticals Research Uk Limited | Use of cannabinoids in the treatment of epilepsy |
| US10137095B2 (en) | 2014-10-14 | 2018-11-27 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
| US12064399B2 (en) | 2015-06-17 | 2024-08-20 | Jazz Pharmaceuticals Research Uk Limited | Use of cannabinoids in the treatment of epilepsy |
| US10709671B2 (en) | 2015-06-17 | 2020-07-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11357741B2 (en) | 2015-06-17 | 2022-06-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| GB2541191A (en) * | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| US11147783B2 (en) | 2015-08-10 | 2021-10-19 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11684598B2 (en) | 2015-08-10 | 2023-06-27 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| EP3769755A1 (en) | 2015-08-10 | 2021-01-27 | GW Research Limited | Use of cannabidiolic acid in the treatment of epilepsy |
| US10583096B2 (en) | 2016-03-31 | 2020-03-10 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11291631B2 (en) | 2016-07-01 | 2022-04-05 | GW Research Limited | Oral cannabinoid formulations |
| US11229612B2 (en) | 2016-07-01 | 2022-01-25 | GW Research Limited | Parenteral formulations |
| US12064398B2 (en) | 2016-07-01 | 2024-08-20 | Jazz Pharmaceuticals Research Uk Limited | Parenteral formulations |
| US12213985B2 (en) | 2016-07-01 | 2025-02-04 | Jazz Pharmaceuticals Research Uk Limited | Oral cannabinoid formulations |
| US11065227B2 (en) | 2016-08-25 | 2021-07-20 | GW Research Limited | Use of cannabinoids in the treatment of multiple myeloma |
| US11679087B2 (en) | 2016-12-16 | 2023-06-20 | GW Research Limited | Use of cannabinoids in the treatment of Angelman syndrome |
| US12616705B2 (en) | 2016-12-16 | 2026-05-05 | Jazz Pharmaceuticals Research Uk Limited | Use of cannabinoids in the treatment of Angelman syndrome |
| US11426362B2 (en) | 2017-02-17 | 2022-08-30 | GW Research Limited | Oral cannabinoid formulations |
| US12161607B2 (en) | 2017-02-27 | 2024-12-10 | Jazz Pharmaceuticals Research Uk Limited | Combination of cannabinoids in the treatment of leukemia |
| US12263139B2 (en) | 2017-06-23 | 2025-04-01 | Jazz Pharmaceuticals Research Uk Limited | Use of cannabidiol in the treatment of tuberous sclerosis complex |
| US12383567B2 (en) | 2017-12-01 | 2025-08-12 | Jazz Pharmaceuticals Research Uk Limited | Use of cannabinoids in the treatment of epilepsy |
| US11806319B2 (en) | 2018-01-03 | 2023-11-07 | GW Research Limited | Pharmaceutical composition comprising a cannabinoid |
| CN108743571B (en) * | 2018-08-07 | 2020-10-02 | 云南汉木森生物科技有限责任公司 | Pharmaceutical composition for preventing and treating epilepsy and preparation method thereof |
| CN108743571A (en) * | 2018-08-07 | 2018-11-06 | 云南汉木森生物科技有限责任公司 | Prevent, treat the pharmaceutical composition and preparation method thereof of epilepsy |
| CN110632224A (en) * | 2019-09-16 | 2019-12-31 | 福建省中科生物股份有限公司 | Establishment method of hemp plant fingerprint spectrum |
| CN110632224B (en) * | 2019-09-16 | 2022-02-15 | 福建省中科生物股份有限公司 | Establishment method of hemp plant fingerprint spectrum |
| US12102619B2 (en) | 2020-02-27 | 2024-10-01 | Jazz Pharmaceuticals Research Uk Limited | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| US11160795B2 (en) | 2020-02-27 | 2021-11-02 | GW Research Limited | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| US11406623B2 (en) | 2020-02-27 | 2022-08-09 | GW Research Limited | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| US12661365B2 (en) | 2020-06-18 | 2026-06-23 | Jazz Pharmaceuticals Research Uk Limited | Use of cannabidiol in the treatment of epilepsy |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
| US12569505B2 (en) | 2022-08-12 | 2026-03-10 | Jazz Pharmaceuticals Research Uk Limited | Oral solid dosage forms comprising cannabinoids |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2737447A1 (en) | Hayley's comet | |
| Jiang | Natural forms of vitamin E: metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy | |
| Kaplan et al. | Adipocyte progenitor cells initiate monocyte chemoattractant protein-1-mediated macrophage accumulation in visceral adipose tissue | |
| Zhou et al. | Oxidative stress in the pathogenesis of psoriasis | |
| Liu et al. | Effects of manganese deficiency on the microstructure of proximal tibia and OPG/RANKL gene expression in chicks | |
| Kipper et al. | Meta-analysis of the effects of endoparasites on pig performance | |
| NZ715957A (en) | Compartmentalized method of nucleic acid delivery and compositions and uses thereof | |
| JP2019535681A5 (en) | ||
| Wang et al. | Application of exogenous auxin and gibberellin regulates the bolting of lettuce (Lactuca sativa L.) | |
| Lauridsen et al. | Composition of α-tocopherol and fatty acids in porcine tissues after dietary supplementation with vitamin E and different fat sources | |
| BR112018072235A2 (en) | formulations and methods for treating photosynthetic organisms and increasing the qualities and quantities of productions with glycan composite formulations | |
| Nguyen et al. | Growth performance and carcass characteristics of Australian prime lambs supplemented with pellets containing canola oil or flaxseed oil | |
| Basuki | Analisis tingkat preferensi petani terhadap karakterisitik hasil dan kualitas bawang merah varietas lokal dan impor | |
| CN104003810A (en) | Rubber tree dead skin prevention and cure smearing agent and preparing method for rubber tree dead skin prevention and cure smearing agent | |
| CA2859927A1 (en) | Gcg genetic fingerprint and hplc profile | |
| JP5070040B2 (en) | Vascular insufficiency improving agent | |
| RU2020119597A (en) | COMPOSITION FOR TREATMENT OF PATIENT WITH RESPIRATORY DISEASE CAUSED BY CHRONIC INFLAMMATORY, METHOD FOR PRODUCING AND APPLICATION OF THIS COMPOSITION | |
| Dąbrowski et al. | Cannabinoids from Cannabis sp.: Mechanism of their activity and potential health benefits in human body | |
| WO2017220044A3 (en) | Bifonazole pharmaceutical composition and liver-protecting effect thereof | |
| Henning et al. | Registration of High Alpha‐Acid Male Hop Germplasm USDA 21267M | |
| TWI702959B (en) | Development of a standardized and effect-optimized herbal extract of wedelia chinensis and its use for treating disease | |
| BR112022011326A2 (en) | CONJUGATE BETWEEN A BIOPOLYMER AND A PHOTOACTIVABLE ANTIMICROBIAL AGENT TO COMBAT FUNGAL DISEASES OF AGRICULTURAL INTEREST AND METHODS FOR THE PRODUCTION OF SUCH CONJUGATES | |
| US20240341254A1 (en) | Varin profiles | |
| Mail et al. | Anti-hyphal properties of potential bioactive compounds for oral rinse in suppression of Candida growth | |
| Liu et al. | Dietary lycopene improves growth performance, antioxidant capacity, alters immune-related biomarkers and gut microbiota in growing geese |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20170922 |